June 8-11, 2023, European Hematology Association
1) A Phase 1, Open Label, Dose Escalation, First-in-Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR-103 in Patients with Relapsed Advanced Malignancies (BHARAT-1)April 14 – 19, 2023, AACR
1) Generation of Profound Anti-Tumor Immunity by AUR-109, A Spectrum-Selective Tyrosine Kinase Inhibitor, Either as a Single Agent or in Combination with Immune Checkpoint Inhibitors2) A Highly Differentiated A2AR InhibitorApril 10-13, 2023, Drug Discovery Chemistry
1) Targeting CBP/p300 – Inhibition vs. Degradation for Potent Anti-Tumor Efficacy
May 10 – 12, 2022, Adenosine-Pathway Targeted Cancer Immunotherapy Summit
Dual Targeting of CD73 & A2AR for Effective Suppression of Adenosine Signaling May 11 2022